Evidence map›Paper›PMID 30215763›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2019

Temporal Trends in Co-trimoxazole Use Among Children on Antiretroviral Therapy and the Impact of Co-trimoxazole on Mortality Rates in Children Without Severe Immunodeficiency.

David C Boettiger, Matthew G Law, Annette H Sohn, Mary-Ann Davies, Kara Wools-Kaloustian, Valeriane Leroy, Marcel Yotebieng, Michael Vinikoor, Rachel Vreeman, Madeleine Amorissani-Folquet and 7 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 8 countries.

David C BoettigerThe Kirby Institute, University of New South Wales, Sydney, Australia.
Matthew G LawThe Kirby Institute, University of New South Wales, Sydney, Australia.
Annette H SohnTREAT Asia/amfAR-Foundation for AIDS Research, Bangkok, Thailand.
Mary-Ann DaviesCentre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, South Africa.
Kara Wools-KaloustianIndiana University School of Medicine, Indianapolis.
Valeriane LeroyINSERM, Laboratoire d'Epidémiologie et Analyses en Santé Publique (LEASP)-UMR 1027, Toulouse, France.
Marcel YotebiengCollege of Public Health, The Ohio State University, Columbus.
Michael VinikoorDepartment of Medicine, University of North Carolina at Chapel Hill.
Rachel VreemanIndiana University School of Medicine, Indianapolis.
Madeleine Amorissani-FolquetDepartment of Paediatrics, University Hospital of Cocody, Abidjan, Côte d'Ivoire.
Andrew EdmondsDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.
Geoffrey FattiKheth'Impilo AIDS Free Living, Cape Town, South Africa.
James BatteRakai Health Science Program, Uganda.
Lorna RennerDepartment of Paediatrics, Korlebu Hospital, Accra, Ghana.
Adebola AdedimejiDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
Azar KariminiaThe Kirby Institute, University of New South Wales, Sydney, Australia.
International Epidemiology Databases to Evaluate AIDS
UNSW Sydney · AUIndiana University School of MedicineAlbert Einstein College of Medicine · USCentre for Infectious Disease Research in Zambia · ZMCentre Hospitalier Universitaire de Cocody · CIInserm · FRKorle Bu Teaching Hospital · GHRakai Health Sciences Program · UGStellenbosch University · ZAThe Ohio State University · USUniversity of Cape Town · ZAUniversity of North Carolina at Chapel Hill · US

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional ConsortiumU01AI069911 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AGGREY SEMWENDERO SEMEERE, Kara Kay Wools-Kaloustian · 2006 to 2026
$57.7M
Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
The Asia-Pacific HIV Research CollaborationU01AI069907 · NIAID · FOUNDATION FOR AIDS RESEARCH · PI ANNETTE H SOHN · 2006 to 2026
$44.8M
WADA (West Africa Database on Antiretroviral Therapy) CollaborationU01AI069919 · NIAID · UNIVERSITY OF BORDEAUX II · PI Didier Koumavi Ekouevi, Antoine Jaquet · 2006 to 2026
$29.9M
NIAID NIH HHS P30 AI050410NIAID NIH HHS U01 AI069907NIAID NIH HHS U01 AI069911NIAID NIH HHS U01 AI069919NIAID NIH HHS U01 AI069924
6 · The paper itself

Abstract

backgroundCo-trimoxazole is recommended for all children with human immunodeficiency virus. In this analysis, we evaluate trends in pediatric co-trimoxazole use and survival on co-trimoxazole in children using antiretroviral therapy (ART).

methodsWe used data collected between January 1, 2006, and March 31, 2016, from the International Epidemiology Databases to Evaluate AIDS. Logistic regression was used to evaluate factors associated with using co-trimoxazole at ART initiation. Competing risk regression was used to assess factors associated with death.

resultsA total of 54113 children were included in this study. The prevalence of co-trimoxazole use at ART initiation increased from 66.5% in 2006 to a peak of 85.6% in 2010 and then declined to 48.5% in 2015-2016. A similar trend was observed among children who started ART with severe immunodeficiency. After adjusting for year of ART initiation, younger age (odds ratio [OR], 1.18 for <1 vs 1 to <5 years of age [95% confidence interval (CI), 1.09-1.28]), lower height-for-age z score (OR, 1.15 for less than -3 vs greater than -2 [95% CI, 1.08-1.22]), anemia (OR, 1.08 [95% CI, 1.02-1.15]), severe immunodeficiency (OR, 1.25 [95% CI, 1.18-1.32]), and receiving care in East Africa (OR, 8.97 vs Southern Africa [95% CI, 8.17-9.85]) were associated with a high prevalence of co-trimoxazole use. Survival did not differ according to co-trimoxazole use in children without severe immunodeficiency (hazard ratio, 1.01 for nonusers versus users [95% CI, 0.77-1.34]).

conclusionsRecent declines in co-trimoxazole use may not be linked to the current shift toward early ART initiation. Randomized trial data might be needed to establish the survival benefit of co-trimoxazole in children without severe immunodeficiency.

Indexed as

AdolescentAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveChildChild, PreschoolDrug Administration ScheduleFemaleHIV InfectionsHumansInfantMaleRisk FactorsSeverity of Illness IndexSurvival RateTrimethoprim, Sulfamethoxazole Drug CombinationAnti-HIV AgentsTrimethoprim, Sulfamethoxazole Drug Combinationantiretroviral therapychildrenco-trimoxazoleHIV

Identifiers

PMID30215763
PMCPMC6831936
OpenAlexW2892222634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.